Idiopathic Pulmonary Fibrosis: Current Pathogenetic Insights and Emerging Therapeutic Strategies

Idiopathic interstitial pneumonias (IIPs) comprise a heterogeneous group of diffuse parenchymal lung disorders, with idiopathic pulmonary fibrosis (IPF) being the most prevalent subtype. Despite its rarity, IPF is associated with a high mortality rate, driving substantial research into its etiology, pathogenesis, diagnostic strategies, and therapeutic interventions. In recent years, multiple novel agents, including the anti-fibrotic candidate PRM-151, have been explored as potential treatments aimed at modifying disease progression and improving patient outcomes.